HCC and NASH: how strong is the clinical demonstration?

Area of Science:

• Hepatology
• Oncology
• Metabolic Diseases

Background:

• Obesity and metabolic syndrome (MS) are global epidemics linked to increased cancer risk.
• In the liver, insulin resistance and fatty liver disease contribute to inflammation and angiogenesis, raising liver cancer incidence.
• Cirrhosis is a primary risk factor for hepatocellular carcinoma (HCC), but nonalcoholic fatty liver disease (NAFLD) may directly cause HCC in some cases.

Purpose of the Study:

• To investigate the association between metabolic syndrome (MS) and hepatocellular carcinoma (HCC) risk.
• To evaluate the impact of MS features on HCC development in patients with chronic liver diseases.
• To inform improved screening guidelines and prophylactic strategies for HCC in MS populations.

Main Methods:

• Review of existing literature on obesity, MS, NAFLD, and HCC.
• Analysis of epidemiological data linking metabolic factors to liver cancer incidence.
• Correlation studies examining MS components and HCC risk in various liver disease contexts.

Main Results:

• MS and its components are associated with an elevated risk of HCC, independent of other liver conditions.
• NAFLD may directly contribute to HCC carcinogenesis, even without cirrhosis.
• MS exacerbates HCC risk in patients with viral hepatitis or alcohol-related liver disease.

Conclusions:

• Metabolic syndrome significantly increases the risk of developing hepatocellular carcinoma.
• Clarifying HCC risk in MS patients is crucial for enhancing screening protocols.
• Developing targeted prophylactic treatments for HCC in MS individuals is warranted.